TP53 and breast cancer: Specifically, simvastatin was found to reduce the migratory and invasive abilities of human epithelial MDA-MB-231 breast cancer cells in vitro by increasing mutant P53 expression and repressing expression of the stem cell marker CD44, which is essential for cell migration.